Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label study of MK0991 in children between 3 to 24 months of age with new
onset fever and neutropenia. The purpose of the study is to investigate plasma drug levels of
caspofungin.